Promising bone-related therapeutic targets for rheumatoid arthritis
Open Access
- 1 October 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 5 (10), 543-548
- https://doi.org/10.1038/nrrheum.2009.175
Abstract
No abstract availableThis publication has 68 references indexed in Scilit:
- Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in miceJCI Insight, 2009
- Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in miceJCI Insight, 2009
- Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trialAnnals Of The Rheumatic Diseases, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Radiological damage in patients with rheumatoid arthritis on sustained remissionAnnals Of The Rheumatic Diseases, 2007
- Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destructionThe Journal of Experimental Medicine, 2006
- CCN1/Cyr61 Is Regulated by the Canonical Wnt Signal and Plays an Important Role in Wnt3A-Induced Osteoblast Differentiation of Mesenchymal Stem CellsMolecular and Cellular Biology, 2006
- Bone Morphogenetic ProteinsGrowth Factors, 2004
- Osteoclast differentiation and activationNature, 2003
- IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJCI Insight, 1999